Skip to main content
. Author manuscript; available in PMC: 2019 Aug 2.
Published in final edited form as: Cancer Discov. 2019 Jan 10;9(4):492–499. doi: 10.1158/2159-8290.CD-18-1314

Figure 3.

Figure 3.

Effect of naïve or SCM percentage and cytokines on expansion potential. A, There is a significant difference in expansion potential when using 25% naïve T cells (P = 0.028) or 25% naïve plus SCM (P = 0.0053) as a cutoff. The green line represents 5-fold expansion. Samples are from time point 0 (diagnosis). B, Addition of IL7 and IL15 to the expansion procedure results in a higher percentage of patient samples surpassing 5-fold expansion in all tumor types (n = 79 patients in total). C, Prechemotherapy/diagnostic samples were separated into three groups based on initial pass rate and response to the addition of IL7 and IL15. Supplementary cytokines did not rescue some samples (fail to improve), rescued others (improve), and always increased the cell number in samples that passed initially without them (already pass). D, Diagnostic/prechemotherapy samples after bead expansion demonstrate a majority of CM T cells in most disease types, with a possible inverse relationship between SCM and effector memory (EM) cells that is not statistically significant. Please see the Methods for the phenotypic definitions of each subset.